3Q2.2. LDL-C 3Q2.3. HDL-C 3Q2.4. Non-HDL-C 3Q2.5. Triglycerides 3Q2.6. Apolipoproteins 3Q2.7. Secondary Causes of Dyslipidemia 3Q2.8. Additional Tests 3Q3. WHAT ARE THE TREATMENT RECOMMENDATIONS IN INDIVIDUALS WITH DYSLIPIDEMIA AND ASCVD RISK? 3Q3.1. Treatment Goals • 3Q3.1.1. Risk Cat...
They further confirm that older persons benefit from therapeutic lowering of LDL-C. The major recommendations for modifications to footnote the ATP III treatment algorithm are the following. In high-risk persons, the recommended LDL-C goal is <100 mg/dL, but when risk is very high, an LDL-...
supported this work for overseas research fellowships (to Dr Ikemura). Dr Ikemura has received an unrestricted research grant from Bristol Myers Squibb for the Department of Cardiology, Keio University School of Medicine. Dr Chan receives funding from the American Heart Association; and is a ...
Use of lipid-lowering drugs to aggressively reduce circulating LDL-C levels can mitigate this increased ASCVD risk [13–15]. Treatment goals for FH patients include first-line treatment with statins [16] and, if needed, the addition of non-statin therapies to achieve an LDL-C target of <100...
Historically, the field of cardiology has been male-dominated, which has led to some unfortunate oversight and gender bias, impacting the treatment of and the screening of heart disease compared to other diseases like cancer. According to the American Heart Association, more women die from heart ...
The greatest clinical benefit was observed in rosuvastatin recipients achieving an LDL-C level of <1.8mmol/L (<70mg/dL) and an hsCRP level of <2mg/L or, even more so, <1mg/L. Rosuvastatin was well tolerated in the JUPITER trial, with most adverse events being mild to moderate in ...
; American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30(1):162-172.10.2337/dc07-9917Search in ...
aAn American Heart Association report summarizes other research info on how monounsaturated oil reduces your risk of heart disease in total. They also explore how a high-MUFA diet can improve the other conditions that contribute to heart disease like lowering LDL and raising HDL Cholesterol, helping...
The American College of Endocrinology held a Consensus Conference in Washington, DC, on 21–22 July 2008 on the topic of pre-diabetes, organized around a series of interrelated questions. This is the second of a three-part series summarizing presentations at the conference. What goals and treatm...
Rosuvastatin has greater lipid-lowering efficacy than any of the other currently available statins, and significantly more patients receiving rosuvastatin than other statins achieve LDL-C goals. Rosuvastatin delayed the progression of carotid atherosclerosis in patients with subclinical carotid atherosclerosis,...